从传统药物到核酸药物治疗心血管疾病
核酸药物因遗传学发现新靶点、递送与安全性进展及可调控传统药物难治靶点而大规模研发。RNA靶向药物如apo(a)-ASO和PCSK9-siRNA已进入大规模临床结局试验,microRNA调控、表观遗传和基因治疗处于早期临床,CRISPR-Cas在干细胞高效但体细胞编辑仍存挑战。
要点
- RNA靶向药物(apo(a)-ASO、PCSK9-siRNA)已进入大规模临床结局试验。
- microRNA调控、表观遗传和基因治疗正在心血管疾病早期临床研究中。
- CRISPR-Cas在干细胞中高效,但体细胞(如心肌细胞)同源定向修复率低。
核心结论
- RNA靶向治疗(如apo(a)-ASO和PCSK9-siRNA)已进入大规模临床结局试验,很可能成为心血管疾病新的有效安全治疗选择。
- microRNA调控、表观遗传和基因治疗正在心血管疾病早期临床研究中测试。
- CRISPR-Cas介导的基因组编辑在干细胞中高效,但在体细胞中仍存重大挑战,该领域发展迅速。
研究设计与样本
- 综述文章,总结核酸药物治疗心血管疾病的研发进展与临床研究现状。
主要发现
- RNA靶向治疗使用反义寡核苷酸(ASO)或短干扰RNA(siRNA)降低apo(a)、PCSK9、apoCIII、ANGPTL3或TTR,用于动脉粥样硬化性心血管疾病或TTR淀粉样变性。
- EMA/FDA已批准基因治疗用于非心脏单基因疾病,LDL受体基因治疗正在纯合子高胆固醇血症患者中检查。
- 实验研究中,基因治疗显著改善心力衰竭动物模型的心脏功能。
- CRISPR-Cas在干细胞中证明强大,但在心肌细胞等体细胞中同源定向修复率低。
局限性
- CRISPR-Cas在体细胞(如心肌细胞)中同源定向修复率低,是基因组编辑的主要挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nucleic acid-based therapeutics are currently developed at large scale for prevention and management of cardiovascular diseases (CVDs), since: (i) genetic studies have highlighted novel therapeutic targets suggested to be causal for CVD; (ii) there is a substantial recent progress in delivery, efficacy, and safety of nucleic acid-based therapies; (iii) they enable effective modulation of therapeutic targets that cannot be sufficiently or optimally addressed using traditional small molecule drugs or antibodies. Nucleic acid-based therapeutics include (i) RNA-targeted therapeutics for gene silencing; (ii) microRNA-modulating and epigenetic therapies; (iii) gene therapies; and (iv) genome-editing approaches (e.g. CRISPR-Cas-based): (i) RNA-targeted therapeutics: several large-scale clinical development programmes, using antisense oligonucleotides (ASO) or short interfering RNA (siRNA) therapeutics for prevention and management of CVD have been initiated. These include ASO and/or siRNA molecules to lower apolipoprotein (a) [apo(a)], proprotein convertase subtilisin/kexin type 9 (PCSK9), apoCIII, ANGPTL3, or transthyretin (TTR) for prevention and treatment of patients with atherosclerotic CVD or TTR amyloidosis. (ii) MicroRNA-modulating and epigenetic therapies: novel potential therapeutic targets are continually arising from human non-coding genome and epigenetic research. First microRNA-based therapeutics or therapies targeting epigenetic regulatory pathways are in clinical studies. (iii) Gene therapies: EMA/FDA have approved gene therapies for non-cardiac monogenic diseases and LDL receptor gene therapy is currently being examined in patients with homozygous hypercholesterolaemia. In experimental studies, gene therapy has significantly improved cardiac function in heart failure animal models. (iv) Genome editing approaches: these technologies, such as using CRISPR-Cas, have proven powerful in stem cells, however, important challenges are remaining, e.g. low rates of homology-directed repair in somatic cells such as cardiomyocytes. In summary, RNA-targeted therapies (e.g. apo(a)-ASO and PCSK9-siRNA) are now in large-scale clinical outcome trials and will most likely become a novel effective and safe therapeutic option for CVD in the near future. MicroRNA-modulating, epigenetic, and gene therapies are tested in early clinical studies for CVD. CRISPR-Cas-mediated genome editing is highly effective in stem cells, but major challenges are remaining in somatic cells, however, this field is rapidly advancing.
引用
- Landmesser U, Poller W, Tsimikas S, et al. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. Eur Heart J. 2020. PMID: 32350510. doi:10.1093/eurheartj/ehaa229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。